# Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)

> **NCT00725842** · — · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 97 (actual)

## Conditions studied

- Hepatitis C
- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** Peg-IFN alfa-2b
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00725842
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 97 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2015-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725842, "Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00725842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*